Shares Held by Insiders

Fully Diluted Shares Held by Insiders

Date

Name

Buy/Sell

$ Value

# Shares

Avg. Price

Title

Chief Executive Officer

See Remarks

President

Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses to develop novel therapeutics to address unmet medical needs in viral and liver diseases. Its lead drug candidate is ALG-097558, which is in Phase I clinical trial for the treatment of coronavirus; and ALG-000184, a capsid assembly modulator, which is completed Phase 1b clinical trial to treat chronic hepatitis B (CHB). The company also develops ALG-055009, a small molecule THR-ÃƒÅ¸ agonist that is in the Phase 2 clinical trial for the treatment of non-alcoholic steatohepatitis (NASH). In addition, it develops siRNA drug candidate, ALG-125755, which is in Phase I clinical trial for the treatment of CHB. Aligos Therapeutics, Inc. has entered into license and collaboration agreements with Luxna Biotech Co., Ltd. to develop and commercialize products containing oligonucleotides targeting hepatitis B virus genome; Emory University to provide hepatitis B virus capsid assembly modulator technology; research, licensing, and commercialization agreement with Katholieke Universiteit Leuven to develop coronavirus protease inhibitors; and Merck to discover, research, optimize, and develop oligonucleotides directed against a NASH, as well as a research collaboration and development agreement with Xiamen Amoytop Biotech Co., Ltd. to research and develop oligonucleotide compounds for the treatment of liver diseases.. The company was incorporated in 2018 and is headquartered in South San Francisco, California.

Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses to develop novel therapeutics to address unmet medical need...

Datesorted ascending	Name	Buy/Sell	$ Value	# Shares	Avg. Price	Title
2023-10-25	Premium	bought	Premium	Premium	Premium	-
2023-10-25	Premium	acquired	Premium	Premium	Premium	-
2023-10-25	Premium	acquired	Premium	Premium	Premium	Chief Executive Officer
2021-06-11	Premium	acquired	Premium	Premium	Premium	-
2021-06-11	Premium	acquired	Premium	Premium	Premium	-
2021-04-26	Premium	acquired	Premium	Premium	Premium	-
2021-04-26	Premium	acquired	Premium	Premium	Premium	-
2020-10-20	Premium	bought	Premium	Premium	Premium	-
2020-10-20	Premium	acquired	Premium	Premium	Premium	See Remarks
2020-10-20	Premium	acquired	Premium	Premium	Premium	President
2020-10-20	Premium	acquired	Premium	Premium	Premium	See Remarks
2020-10-20	Premium	acquired	Premium	Premium	Premium	-
2020-10-20	Premium	acquired	Premium	Premium	Premium	-
2020-10-20	Premium	bought	Premium	Premium	Premium	-
2020-10-20	Premium	acquired	Premium	Premium	Premium	-
2020-10-20	Premium	acquired	Premium	Premium	Premium	-
2020-10-20	Premium	acquired	Premium	Premium	Premium	Chief Executive Officer
2020-10-20	Premium	acquired	Premium	Premium	Premium	-
2020-10-20	Premium	bought	Premium	Premium	Premium	-
2020-10-20	Premium	bought	Premium	Premium	Premium	-
2020-10-20	Premium	acquired	Premium	Premium	Premium	-
2020-10-20	Premium	acquired	Premium	Premium	Premium	-
2020-10-20	Premium	bought	Premium	Premium	Premium	-
2020-10-20	Premium	acquired	Premium	Premium	Premium	-

ALGS - Aligos Therapeutics Inc Stock Price, Fair Value and News

Latest Insider Trading transactions for ALGS